| The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer, Braga F, Ferraro S, Mozzi R and Panteghini M, 2014, Clin Chem Lab Med, 52, 1625-31 | 9.1 | 10.6 | Females | Healthy (excl pregnant) | Serum |
| Assessment of biological variation and analytic impreciion of CA 125, CEA and TPA in relation to monitoring of ovarian cancer, Tuxen MK, Solétormos G, Pertersen PH, Cioler V, Dombernovsky P, 1999, Gynecologic Oncology, 74, 12-22 | 23.3 | 70.6 | Females | Healthy (excl pregnant) | Serum |
| Biological variation of tumor markers and its aplication in the detection of disease progression in patients with non-samll cell lung cancer, Trapé J, Perez de Olaguer J, Buxó J and López L, 2005, Clin Chem, 51, 219-22 | 21.1 | 36.3 | Males | Non-healthy (excl pregnant) | Serum |
| Interpretation of sequential measurements of cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer, Tuxen MK, Sölétormos G, Petersen PH and Dombernowsky P, 2001, Clin Chem Lab Med, 39, 531-8 | 20.0 | | Females | Healthy (excl pregnant) | Serum |
